News
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...
SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.
Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...
1d
Pharmaceutical Technology on MSNFDA free to pursue semaglutide compounders after latest court rulingDespite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...
A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...
A federal judge in Texas handed Novo Nordisk (NVO) a big win late Thursday in its battle against cheaper versions of its ...
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...
Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...
Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...
Sven Knudsen Ljaamo, MD, a Veterans Affairs' physician in Massachusetts, was charged with possessing child sexual abuse ...
Varenicline helped teens and young adults quit nicotine vapes when provided in conjunction with brief cessation counseling, a ...
Eli Lilly (LLY) is scheduled to release its Q1 earnings on May 1, and analysts continue to stay positive, holding onto Buy ratings for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results